Brendan Hannah - 24 Oct 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Chief Business Officer and COO
Signature
/s/ Brendan Hannah
Issuer symbol
QNCX
Transactions as of
24 Oct 2023
Net transactions value
$0
Form type
4
Filing time
26 Oct 2023, 17:54:48 UTC
Previous filing
09 Aug 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Employee Stock Option (right to buy) Award $0 +75,000 $0.000000 75,000 24 Oct 2023 Common Stock 75,000 $0.9900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares subject to the option shall vest and become exercisable on each monthly anniversary of the vesting commencement date of October 23, 2023.